世界の重複がん早期検出市場2022-2028:種類別(リキッドバイオプシー、遺伝子パネル、LDT、その他)、エンドユーザー別、地域別

【英語タイトル】Global Multi Cancer Early Detection Market Size study, By Type (Liquid Biopsy, Gene Panel, LDT, & Others), By End-User (Hospitals, Diagnostic Laboratories, Others), and Regional Forecasts 2022-2028

Bizwit Research & Consultingが出版した調査資料(BZW22DC061)・商品コード:BZW22DC061
・発行会社(調査会社):Bizwit Research & Consulting
・発行日:2022年9月29日
・ページ数:約200
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:アメリカ、カナダ、イギリス、ドイツ、フランス、スペイン、イタリア、中国、インド、日本、オーストラリア、韓国、ブラジル、メキシコ、中東
・産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用、印刷不可)USD4,950 ⇒換算¥732,600見積依頼/購入/質問フォーム
Enterprisewide(同一法人内共有可)USD6,250 ⇒換算¥925,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

Bizwit Research社発行の本調査レポートによると、2021年におよそ791.58百万ドルであった世界の重複がん早期検出市場規模が、2022年から2028年の間に15.0%以上成長すると予測されています。本レポートは、重複がん早期検出の世界市場を対象とし、エグゼクティブサマリー、市場定義・範囲、市場動向、産業分析、リスク分析(新型コロナウイルス感染症の影響)、種類別(リキッドバイオプシー、遺伝子パネル、LDT、その他)分析、エンドユーザー別(病院、診断研究所、その他)分析、地域別(北米、ヨーロッパ、アジア太平洋、中南米、その他地域)分析、競争分析、調査プロセスなど、多面的な分析結果をまとめたものです。なお、参入企業情報として、Grail, LLC (Illumina, Inc.)、Illumina, Inc.、Exact Sciences Corporation.、Foundation Medicine, Inc.、AnchorDx、Guardant Health, Inc.、Burning Rock Biotech Limited、GENECAST、Laboratory for Advanced Medicine, Inc.、Singlera Genomics Incなどが含まれております。
・エグゼクティブサマリー
・市場定義・範囲
・市場動向
・産業分析
・リスク分析(新型コロナウイルス感染症の影響)

・世界の重複がん早期検出市場規模:種類別
- リキッドバイオプシーの市場規模
- 遺伝子パネルの市場規模
- LDTの市場規模
- その他種類の市場規模

・世界の重複がん早期検出市場規模:エンドユーザー別
- 病院における市場規模
- 診断研究所における市場規模
- その他エンドユーザーにおける市場規模

・世界の重複がん早期検出市場規模:地域別
- 北米の重複がん早期検出市場規模
- ヨーロッパの重複がん早期検出市場規模
- アジア太平洋の重複がん早期検出市場規模
- 中南米の重複がん早期検出市場規模
- その他地域の重複がん早期検出市場規模

・競争分析
・調査プロセス

Global Multi Cancer Early Detection Market is valued at approximately USD 791.58 million in 2021 and is anticipated to grow with a healthy growth rate of more than 15.0% over the forecast period 2022-2028.
Multi-cancer detection (MCD) measure biological signals that may be released by cancer cells in bodily fluids. These indicators are frequently referred to as tumour markers or biomarkers. MCD assays are being created to simultaneously screen for malignancies in multiple organ sites. The market for multi cancer early detection (MCED) is anticipated to expand as a result of factors such as the rising incidence of cancer and the government’s increased emphasis on cancer early detection. According to the WHO, cancer will account for about 10 million deaths in 2020, or almost one in every six deaths worldwide. One-third of cancer-related deaths are caused by variables such as smoking, having a high body mass index, drinking, being obese, and having high cholesterol. Because early cancer detection can increase patient survival and save treatment costs, there is a rising business opportunity. According to estimates from the International Agency for Research on Cancer (IARC), globally, there were 17.0 million new instances of cancer and 9.5 million cancer-related deaths in 2018. It is estimated to increase the worldwide burden of cancer to 27.5 million new cases by 2040. Also, need to develop diagnostic options that can detect cancer at an early stage and increased dependence of hospitals on diagnostic laboratories for testing and evaluation are anticipated to act as catalyzing factors for the market demand during the forecast period. However, collection of adequate safety and efficacy data for regulatory approval may impede the growth of the market over the forecast period of 2022-2028.

The key regions considered for the global Multi Cancer Early Detection market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. Europe is the leading region across the world in terms of market share owing to the increased funding in R&D and the increased prevalence of cancer in the region. Whereas, North America is anticipated to exhibit a significant growth rate over the forecast period 2022-2028. Factors such as the rising prevalence of cancer, and rising technological advancement in the region are fueling the growth of market.

Major market players included in this report are:
Grail, LLC (Illumina, Inc.)
Illumina, Inc.
Exact Sciences Corporation.
Foundation Medicine, Inc.
AnchorDx
Guardant Health, Inc.
Burning Rock Biotech Limited
GENECAST
Laboratory for Advanced Medicine, Inc.
Singlera Genomics Inc

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type:
Liquid Biopsy
Gene Panel, LDT, & Others

By End-User:
Hospitals
Diagnostic Laboratories
Others

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Multi Cancer Early Detection Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

❖ レポートの目次 ❖

Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2020-2028 (USD Million)
1.2.1. Multi Cancer Early Detection Market, by Region, 2020-2028 (USD Million)
1.2.2. Multi Cancer Early Detection Market, by Type, 2020-2028 (USD Million)
1.2.3. Multi Cancer Early Detection Market, by End-User, 2020-2028 (USD Million)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Multi Cancer Early Detection Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Multi Cancer Early Detection Market Dynamics
3.1. Multi Cancer Early Detection Market Impact Analysis (2020-2028)
3.1.1. Market Drivers
3.1.1.1. Increasing prevalence of cancer
3.1.1.2. Extensive R&D for the development of MCED
3.1.2. Market Challenges
3.1.2.1. Collection of adequate safety and efficacy data for regulatory approval
3.1.3. Market Opportunities
3.1.3.1. Need to develop diagnostic options that can detect cancer at an early stage
3.1.3.2. Increased dependence of hospitals on diagnostic laboratories for testing and evaluation
Chapter 4. Global Multi Cancer Early Detection Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model (2018-2028)
4.2. PEST Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
4.5. Top investment opportunity
4.6. Top winning strategies
Chapter 5. Risk Assessment: COVID-19 Impact
5.1.1. Assessment of the overall impact of COVID-19 on the industry
5.1.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global Multi Cancer Early Detection Market, by Type
6.1. Market Snapshot
6.2. Global Multi Cancer Early Detection Market by Type, Performance – Potential Analysis
6.3. Global Multi Cancer Early Detection Market Estimates & Forecasts by Type, 2018-2028 (USD Million)
6.4. Multi Cancer Early Detection Market, Sub Segment Analysis
6.4.1. Liquid Biopsy
6.4.2. Gene Panel, LDT,& Others
Chapter 7. Global Multi Cancer Early Detection Market, by End-User
7.1. Market Snapshot
7.2. Global Multi Cancer Early Detection Market by End-User, Performance – Potential Analysis
7.3. Global Multi Cancer Early Detection Market Estimates & Forecasts by End-User, 2018-2028 (USD Million)
7.4. Multi Cancer Early Detection Market, Sub Segment Analysis
7.4.1. Hospitals
7.4.2. Diagnostic Laboratories
7.4.3. Others
Chapter 8. Global Multi Cancer Early Detection Market, Regional Analysis
8.1. Multi Cancer Early Detection Market, Regional Market Snapshot
8.2. North America Multi Cancer Early Detection Market
8.2.1. U.S. Multi Cancer Early Detection Market
8.2.1.1. Type breakdown estimates & forecasts, 2018-2028
8.2.1.2. End-User breakdown estimates & forecasts, 2018-2028
8.2.2. Canada Multi Cancer Early Detection Market
8.3. Europe Multi Cancer Early Detection Market Snapshot
8.3.1. U.K. Multi Cancer Early Detection Market
8.3.2. Germany Multi Cancer Early Detection Market
8.3.3. France Multi Cancer Early Detection Market
8.3.4. Spain Multi Cancer Early Detection Market
8.3.5. Italy Multi Cancer Early Detection Market
8.3.6. Rest of Europe Multi Cancer Early Detection Market
8.4. Asia-Pacific Multi Cancer Early Detection Market Snapshot
8.4.1. China Multi Cancer Early Detection Market
8.4.2. India Multi Cancer Early Detection Market
8.4.3. Japan Multi Cancer Early Detection Market
8.4.4. Australia Multi Cancer Early Detection Market
8.4.5. South Korea Multi Cancer Early Detection Market
8.4.6. Rest of Asia Pacific Multi Cancer Early Detection Market
8.5. Latin America Multi Cancer Early Detection Market Snapshot
8.5.1. Brazil Multi Cancer Early Detection Market
8.5.2. Mexico Multi Cancer Early Detection Market
8.6. Rest of The World Multi Cancer Early Detection Market

Chapter 9. Competitive Intelligence
9.1. Top Market Strategies
9.2. Company Profiles
9.2.1. Grail, LLC
9.2.1.1. Key Information
9.2.1.2. Overview
9.2.1.3. Financial (Subject to Data Availability)
9.2.1.4. Product Summary
9.2.1.5. Recent Developments
9.2.2. Illumina, Inc.
9.2.3. Exact Sciences Corporation.
9.2.4. Foundation Medicine, Inc.
9.2.5. AnchorDx
9.2.6. Guardant Health, Inc.
9.2.7. Burning Rock Biotech Limited
9.2.8. GENECAST
9.2.9. Laboratory for Advanced Medicine, Inc.
9.2.10. Singlera Genomics Inc.
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption



★調査レポート[世界の重複がん早期検出市場2022-2028:種類別(リキッドバイオプシー、遺伝子パネル、LDT、その他)、エンドユーザー別、地域別] (コード:BZW22DC061)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の重複がん早期検出市場2022-2028:種類別(リキッドバイオプシー、遺伝子パネル、LDT、その他)、エンドユーザー別、地域別]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆